Biocon recorded a net loss of ₹42 crore in Q3 FY23 as against a profit of ₹187 crore in the same quarter last year, on account of an extraordinary item of ₹271 crore related to expenses associated with the Viatris purchase.
The company saw its net revenue grow 35.28 per cent to ₹2,941 crore, compared with ₹2,174 crore in the December quarter last year.
“We expect to end FY23 on a strong note with healthy growth across businesses. Biocon Biologics is tracking towards exiting the year at a $1-billion trajectory, excluding vaccines,” said Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics.
The company said revenue grew on the back of robust performances across all three of its businesses. The biosimilars business reported a 54 per cent increase in revenue to ₹1,507 crore. Research services reported a 23 per cent revenue growth at ₹786 crore and the generics business grew 18 per cent to ₹18 crore.
“The advancement of our research pipeline led to ₹337 crore in net R&D investments this quarter, which will drive Biocon’s future growth. As a part of our strategy to reduce the acquisition debt, Biocon has raised funds through a partial divestment of its stake in Syngene,” according to a release.
In Q3, the company also announced negative earnings per share of ₹0.35 compared to ₹1.54 in Q3 FY22.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.